Related Experiment Video
Updated: Jan 30, 2026

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
Published on: August 1, 2019
Redox Dual-Responsive and O2‑Evolving Theranostic Nanosystem for Highly Selective Chemotherapy against Hypoxic Tumors
Huachao Chen1, Fei Li2, Yongrong Yao1
1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Abstract:
Activatable theranostic agents, which combine fluorescent reporters with masked chemotherapeutic agents that are activated by tumor-associated stimuli, would be attractive candidates to improve the tumor selectivity of chemotherapy. This work reports a ROS/GSH dual-activatable and O2‑evolving theranostic nanosystem (RA-S-S-Cy@PLGA NPs) for highly selective therapy against hypoxic tumors and in situ fluorescence-tracking of cancer chemotherapy. Methods: In this system, the newly designed theranostic agent (RA-S-S-Cy) is composed of a disulfide bond as a cleavable linker, a near infrared (NIR) active fluorophore as a fluorescent tracker, and a natural cyclopeptide RA-V as the active anti-cancer agent. Upon reaction with the high level of intracellular glutathione (GSH), disulfide cleavage occurs, resulting in concomitant active drug RA-V release and significant NIR fluorescence increase. To further improve the tumor targeting of RA-S-S-Cy and achieve redox dual-responsiveness, RA-S-S-Cy was incorporated into the c(RGDfK)-targeted PLGA nanoparticles together with an O2-generating agent (catalase) to produce RA-S-S-Cy@PLGA NPs. Results: The cell-specific and redox dual-activatable release of RA-V lead to enhanced therapeutic outcomes in vivo and in vitro. More significantly, the RA-S-S-Cy@PLGA NPs were successfully applied for monitoring of drug release and chemotherapeutic efficacy in situ by "turn-on" NIR fluorescence. Conclusions: RA-S-S-Cy@PLGA NPs would be efficient theranostic nanosystems for more precise therapy against hypoxic tumors and provides a potential tool for deeper understanding of drug release mechanisms.
Insights
This study introduces a novel dual-activatable theranostic nanosystem for targeted chemotherapy in hypoxic tumors. The system enables precise drug delivery and real-time monitoring of treatment efficacy using near-infrared fluorescence.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Activatable theranostic agents offer improved tumor selectivity by combining fluorescent reporters with masked chemotherapeutics activated by tumor-specific stimuli.
- Hypoxic tumors present a challenge for conventional chemotherapy, necessitating targeted delivery systems.
- Developing systems for in situ monitoring of drug release and therapeutic response is crucial for optimizing cancer treatment.
Purpose of the Study:
- To develop a reactive oxygen species (ROS)/glutathione (GSH) dual-activatable and oxygen (O2)-evolving theranostic nanosystem for selective chemotherapy in hypoxic tumors.
- To enable in situ fluorescence tracking of cancer chemotherapy using near-infrared (NIR) imaging.
- To investigate the therapeutic efficacy and drug release mechanisms of the developed nanosystem.
Main Methods:
- A novel theranostic agent (RA-S-S-Cy) was synthesized, comprising a disulfide linker, an NIR fluorophore, and the active anti-cancer drug RA-V.
- The RA-S-S-Cy agent was encapsulated into c(RGDfK)-targeted poly(lactic-co-glycolic acid) (PLGA) nanoparticles along with catalase to create RA-S-S-Cy@PLGA NPs, designed for dual redox responsiveness and O2 evolution.
- In vitro and in vivo studies were conducted to evaluate drug release, fluorescence tracking, and therapeutic outcomes in hypoxic tumor models.
Main Results:
- The RA-S-S-Cy@PLGA NPs demonstrated cell-specific and redox dual-activatable release of the RA-V drug, leading to enhanced therapeutic effects.
- The nanosystem successfully enabled in situ monitoring of drug release and chemotherapeutic efficacy through 'turn-on' NIR fluorescence.
- Significant improvements in therapeutic outcomes were observed in vivo and in vitro due to targeted drug delivery and activation.
Conclusions:
- RA-S-S-Cy@PLGA NPs represent efficient theranostic nanosystems for precise therapy against hypoxic tumors.
- The developed system provides a valuable tool for understanding drug release mechanisms in real-time.
- This approach holds promise for advancing targeted cancer chemotherapy and improving treatment monitoring.
Related Concept Videos
Balancing Redox Equations
Redox Reactions
Redox Reactions
Dose-Response Relationship: Selectivity and Specificity
Redox Equilibria: Overview
Redox Titration: Overview

